295 filings
8-K
OGEN
Oragenics Inc
19 Apr 24
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
5:48pm
8-K
OGEN
Oragenics Inc
15 Apr 24
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
8:01pm
8-K
OGEN
Oragenics Inc
18 Mar 24
Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion
7:38am
8-K
OGEN
Oragenics Inc
1 Mar 24
Oragenics Announces Closing of Public Offering
4:05pm
8-K
OGEN
Oragenics Inc
28 Feb 24
Oragenics Announces Pricing of Public Offering
9:03am
8-K
rfe2jcc
27 Feb 24
Oragenics Announces Proposed Public Offering
5:48pm
8-K
vrljd1lzdsyk5
12 Feb 24
Oragenics, Inc. Announces Leadership Transition
4:45pm
8-K
rger31d3 4q7x
7 Feb 24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
8:00am
8-K
5c173ahszc4wy tmc
5 Feb 24
Other Events
8:00am
8-K
4j30ddlqvy mls
23 Jan 24
Oragenics Announces Termination of At-The-Market Offering Program
5:18pm
8-K
ayv 29n1u6
16 Jan 24
Other Events
9:10am
8-K
pn2afsk xf4ss4
2 Jan 24
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
9:22am
8-K
wr1jx87 4y
29 Dec 23
Completion of Acquisition or Disposition of Assets
7:30am
8-K
2ri0f1z9ek1vdd fn
15 Dec 23
Material Modifications to Rights of Security Holders
3:45pm
8-K
2d7bhb8m ca8b
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
eggu rijsr
20 Nov 23
Regulation FD Disclosure
3:45pm
8-K
u6eue4u8jf 2ver
2 Nov 23
Oragenics Issues Update to Shareholders
7:00am
8-K
tzjokgcb4ox wsnymvd
5 Oct 23
Departure of Directors or Certain Officers
5:29pm
8-K
vne bb5zi1tryooqk8
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
vf18nfpk t48uq6ek
29 Sep 23
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
4:00pm